wclc 2022 amivantamab

Grade 3/4 TRAEs were mainly liver enzyme elevations. The patients were aged a median of 70 years and 58% were women, reflecting the demographics of NSCLC patients with METex14 mutations, while 53% were nonsmokers, 51% were Asian and 18% had a history of brain metastases, the presenter said. medwireNews: Fresh findings from the phase 1CHRYSALIS and CHRYSALIS-2 trials have been presented at the 2022 ASCO Annual Meeting in Chicago, Illinois, USA, adding support for the use of amivantamab in certain groups of patients with advanced non-small-cell lung cancer (NSCLC). 2022 EGFR Lung Cancer Resisters. With todays approval, for the first time, patients with nonsmall cell lung cancer with EGFR exon 20 insertion mutations will have a targeted treatment option.. Seventy percent of patients were progression-free; in 2 additional cases, the treatment was ongoing beyond RECIST progression. Presidential Symposium Findings Jan 30, 2021 . At the 2021 World Conference on Lung cancer, early results demonstrating amivantamab activity in MET-driven NSCLC from the CHRYSALIS study were presented. Presentations at the International Association for the Study of Lung Cancer (IASLC) 2022 World Conference on Lung Cancer (WCLC) Span Relapsed/Refractory Disease and Frontline Treatment in Patients with EGFR-Positive Non-Small Cell Lung Cancer July 26, 2022 (RARITAN, N.J.) Amivantamab has demonstrated efficacy and safety in patients (pts) with EGFR exon 20 insertion (Exon20ins) in the ongoing CHRYSALIS phase 1 study in advanced non-small cell lung cancer (aNSCLC). 2022IASLCWCLC2022 869+ WCLC EGFR TKIEGFR WCLC CHRYSALIS-2LACPEGFR TKIORR50%! Additional updates will be presented at the International Association for the Study of Lung Cancer (IASLC) 2022 World Conference on Lung Cancer (WCLC), according to Janssen. Five percent of patients in the doublet group developed drug-related ILD grade 1/2; grade 3 events emerged in 3% and 2%, respectively. Median OS was 15.7 months for sotorasib plus any checkpoint inhibitor. Login to view comments. Safety and tolerability represented the first endpoint. Oral daily sotorasib doses of 120mg, 240mg, 360mg, 720mg, and 960mg were tested. An overall response rate of 36% was achieved and the clinical benefit rate was 73%. CapmatinibINC280FDAMETex14NSCLC (2020.5)MET14NSCLC IIGEOMETRY mono-1 BIRC68%ORR48METex14ORR41 12.69.7 The concurrent treatment group, on the other hand, received sotorasib plus atezolizumab (n=10) or pembrolizumab (n=19) from the beginning. Daphne Dumoulin, MD about Lurbinectedin in Pre-Treated Patients With Small Cell Lung Cancer and Malignant Pleural Mesothelioma in a Real World Setting, PODCAST with Dr. Johnson about Durvalumab Tremelimumab + Chemotherapy as First-line Treatment for mNSCLC: Results from the Phase 3 POSEIDON Study, PODCAST with Dr. Alexander Spira about Mobocertinib in EGFR Exon 20 InsertionPositive Metastatic NSCLC Patients With Disease Control on Prior EGFR TKI Therapy, Podcast with dr. Zev Wainberg about the preliminary data from a phase 1b trial evaluating the safety and efficacy of tiragolumab combined with atezolizumab for patients with metastatic oesophageal cancer, In this podcast, Dr. Lisa Salvatore discusses the primary analysis results of the phase II AVANA study, which evaluated preoperative chemoradiotherapy, combined with avelumab, in patients with locally advanced rectal cancer, In this podcast, Dr. Zev Wainberg discusses preliminary data from a phase 1b trial evaluating the safety and efficacy of tiragolumab combined with atezolizumab for patients with metastatic oesophageal cancer, PODCAST with dr. Lisa Salvatore about the primary analysis results of the phase II AVANA study, which evaluated preoperative chemoradiotherapy, combined with avelumab, in patients with locally advanced rectal cancer, PODCAST with prof. Thomas Powles about Keynote-426: Pembrolizumab plus axitinib as a first-line treatment option for patients with advanced clear cell renal cell carcinoma, PODCAST with dr. Josephine Lopes Cardozo: outcomes of patients with an ultralow risk 70-gene signature in the MINDACT trial, PODCAST with Prof. Karim Fizazi: first results of the PEACE-1 trial in men with de novo metastatic castration-sensitive prostate cancer, PODCAST with dr. Thierry Andr about the final overall survival results of the Keynote-177 trial, PODCAST with dr. Leisha Emens about the influence of the tumour microenvironment on the clinical outcomes of triple-negative breast cancer patients who are treated with atezolizumab plus nab-paclitaxel, podcast with dr. Kai Keen Shiu about the phase III KEYNOTE-177 study, Podcast with dr. Zev Wainberg about the phase II FIGHT study, Podcast with prof. dr. Eric Van Cutsem about the phase II study evaluating first-line treatments of unresectable mCRC, Podcast with prof.dr. (WCLC) 2020 on January 29. . Overall, 40 and 48 patients received the doublet and triplet approaches, respectively. Amivantamab was given at a weekly dose of 1050 mg (bodyweight <80 kg) or 1400 mg (80 kg) for the 4-week cycle and twice weekly thereafter alongside lazertinib 240 mg/day. Across all cohorts, deep and durable responses were noted, which included treatment at low doses. Responses proved durable; after a median follow-up of 7.1 months, 15 patients remained on treatment. Highlights Newsletter 1 . Tepotinib was generally well tolerated, with most AEs being mild to moderate. Chow, Video interview with Prof. Jean-Pascal Machiels, Video interview with Geertjan van Tienhoven, Video interview with Prof. Jonathan Ledermann, Video interview with Prof. Bernard Escudier, Video interview with Prof. Daniel Petrylak, Video-interview with Prof. Dr. Nicholas James, Video-interview with Prof. Dr. Gnter von Minckwitz, Video interview with prof. dr. E. Van Cutsem, Video interview with Prof. Wiebren Tjalma, Video interview with Prof. Dr. Veronique Cocquyt, Video interview with professor J. O'Sullivan, Video interview with Professor E. van Cutsem, Video interview with Prof. Philippe Collard, Podcast with Prof. Erika Martinelli about evidence of therapeutic effectiveness of third-line cetuximab rechallenge in appropriately selected patients with metastatic colorectal cancer, Podcast with Prof. Arndt Vogel about the outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the Phase 3 HIMALAYA study, Podcast with Dr. Daniele Rossini about modified FOLFOXIRI plus panitumumab (mFOLFOXIRI/PAN) versus mFOLFOX6/PAN as initial treatment of unresectable RAS/BRAF wild-type metastatic colorectal cancer (mCRC) patients (TRIPLETE study), Podcast with Prof. Melina Marmarelis about the safety and efficacy of amivantamab and lazertinib in combination with platinum-based chemotherapy in relapsed/refractory EGFR-mutated NSCLC, Podcast with Prof. Johan Vansteenkiste about the challenges and opportunities with immunotherapy in the treatment of patients with squamous cell carcinoma of the lung, Podcast with Dr. Laurence Buisseret about first-line chemoimmunotherapy with durvalumab, paclitaxel, and carboplatin with or without the anti-CD73 antibody oleclumab to treat advanced or metastatic triple-negative breast cancer, Podcast with Prof. Richard S. Finn about lenvatinib plus pembrolizumab vs. lenvatinib as first-line therapy for advanced hepatocellular carcinoma, Podcast with Prof. Jean-Pascal Machiels about the primary results of the phase 3 KEYNOTE-412 study: pembrolizumab with chemoradiation vs. placebo plus chemoradiation for locally advanced head and neck squamous cell carcinoma, Podcast with Prof. Anne Demols and Prof. Francesco Sclafani about the highlights from ESMO 2022 on gastrointestinal cancer, Podcast with Prof. Christof Vulsteke about the highlights from ESMO 2022 on gynaecological cancer, Podcast with Dr. Willem Lybaert about the highlights from ESMO 2022 on head and neck cancer, Podcast with Prof. Lore Decoster about the highlights from ESMO 2022 on lung cancer, Designed by Ariez International BV, The Netherlands, Amivantamab monotherapy demonstrates antitumour activity in METex14 NSCLC. and in combination with carboplatin plus pemetrexed after osimertinib, respectively. At WCLC 2022, Li et al. Monday, October 31, 2022. . In the METex14 cohort, patients with METex14 NSCLC whose disease progressed on or who declined current standard of care were treated at the recommended phase II dose of 1,050 mg (1,400 mg 80 kg) weekly in cycle 1 and biweekly thereafter. A Study of . . 20225 (OS)24170% (PFS)7.3 (>20%) 4006-130-650! We are a group of lung cancer patients with EGFR mutations who have developed resistance to at least one targeted treatment drug, or who face probable resistance in the future. The data presented at WCLC included patients in the post-platinum setting who harbored exon 21 insertion mutations, were treated at the RP2D for the safety analysis (n = 114), and had 3 or more disease assessments at clinical cut-off as part of the efficacy population (n = 81). | EGFR. TEAEs due to Dato-DXd led to discontinuation in 15% and 10%, respectively. [1]. No fatal TRAEs occurred. 2022 MJH Life Sciences and Cancer Network. egfr tki 2022-09-28 16:23:30 2022-09-28 The approval of the MET inhibitor tepotinib for the treatment of advanced lung cancer with MET exon 14 (METex14) skipping mutations was mainly based on the results obtained in Cohort A of the phase II VISION study [3]. DOI: 10.1200/JCO.2022.40.16_suppl.9006 Journal of Clinical Oncology - published online before print June 2, 2022 Amivantamab and lazertinib in patients with EGFR-mutant non-small cell lung (NSCLC) after progression on osimertinib and platinum-based chemotherapy: Updated results from CHRYSALIS-2. Ongoing responses were reported for 11 of the 15 patients and 10 patients had responded for 6 months or longer. 2022324,(Brigatinib),ALK(NSCLC) ALTA-1LIIIALK University of Colorado Cancer Center. Presented at the 2021 World Conference on Lung Cancer; Abstract OA15.03. No new safety signals occurred, and most AEs were graded as 1 or 2. Amivantamab previously received priority review and breakthrough therapy designations from the FDA for this indication. Raritan, NJ: Janssen; December 3, 2020. Treatment-related grade 3 adverse events were reported in three patients (16%) and included dyspnoea, hypoalbuminaemia and rash (N= 1, each). Based on these observations, low-dose sotorasib as a lead-in regimen followed by the combination with pembrolizumab will be further studied as first-line treatment in patients with advanced NSCLC. Read More. 2022 WCLC CHRYSALISEEGFR exon19delL858RNSCLC Amivantamab+Lazertinib RECIST v1.1 20 EGFR ex19delL858R119 20211122.34.2-25.3ORR100%mDORmPFS Eight out of nine patients who responded are still in response. Click here to Login. In addition, the safety profile of amivantamab in this subgroup of patients with METex14 is consistent with previously reported experience of patients with EGFR-mutated NSCLC. Initial results for the TROP2-targeting antibody drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd) in addition to pembrolizumab with or without platinum chemotherapy were presented by Levy et al. Furthermore, this group comprised nine treatment-nave individuals, 18 who had received a median 1.5 lines of prior treatment not including a METTKI, and 28 who had received a median 3.0 lines of treatment that included the METTKIs tepotinib or capmatinib. Image for IASLC-WCLC 2022: Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy in Relapsed/Refractory EGFR-mutant NSCLC - imageId : 247240 Cancer Trial Results All Data Conferences Kaplan-Meier Plot Forest Plot Influencers menu clear All Data Conferences Kaplan-Meier Plot Forest Plot Influencers Feedback Privacy Policy In one patient group, a lead-in regimen of sotorasib was administered for 21 or 42 days followed by the combination with atezolizumab (n=10) or pembrolizumab (n=19) Q3W.